Join the club for FREE to access the whole archive and other member benefits.

Implantable cell pouches as living medicines to treat chronic diseases

09-Aug-2021

Key points from article :

Crystal Nyitray, CEO & Co-founder of Encellin, provided an overview of the company’s emerging cell tech to treat chronic disorders.

- Recently announced the closing of a $5.9 million Seed financing round.

- Encellin developed a way to protect implanted cells and the host from rogue cells.

- Our technology can empower cells to be living medicines in the body.

- Invented a soft cell encapsulation device (CED) that functions like a pouch to hold and help cells survive in the body.

- CED allows enclosed cells to function like smart molecular factories, releasing therapeutics when and where needed.

- Building a pipeline of cell-based therapies focusing on high unmet clinical needs.

- We will also work with hospitals and payers to ensure patient accessibility.

- Encellin is a preclinical stage company, with proof of concept in animals. Lead programs are at the doorstep to clinical entry.

Encellin's encapsulation device protects implanted cells, promising targeted cell therapy

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

CEO and Co-founder of Encellin

Company

Cell-based therapeutics to help patients with chronic unmet clinical needs